Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The objective of this phase II study is to evaluate efficacy and safety of avastin plus
modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five
patients will be enrolled into this study.